Bacil Pharma

how big is Bacil Pharma?

As of May 05, Bacil Pharma Ltd has a market capitalization of 24.00 Cr, categorizing it as a Micro Cap company, with net sales of 0.00 Cr and a net profit of 0.35 Cr over the latest four quarters. Shareholder's funds are reported at 1.21 Cr, and total assets amount to 1.27 Cr as of the latest annual period ending in Mar'24.

Market Cap: As of May 05, Bacil Pharma Ltd has a market capitalization of 24.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which includes Dec'24, Sep'24, Jun'24, and Mar'24, is 0.00 Cr. The sum of Net Profit for the same quarters is 0.35 Cr. This data is presented on a Standalone basis.<BR><BR>Balance Sheet Snapshot: This is Standalone data for the latest annual period ending in Mar'24. The Shareholder's Funds are reported at 1.21 Cr, while Total Assets amount to 1.27 Cr.

Is Bacil Pharma overvalued or undervalued?

As of November 17, 2023, Bacil Pharma is considered risky and overvalued with a PE ratio of 24.47 and a troubling ROCE of -13.29%, despite a strong one-year stock return of 70.54%, contrasting with a year-to-date decline of 27.35%.

As of 17 November 2023, Bacil Pharma's valuation grade has moved from does not qualify to risky, indicating a shift in its perceived financial health. The company appears to be overvalued given its current metrics, particularly with a PE ratio of 24.47, a Price to Book Value of 14.48, and a troubling ROCE of -13.29%. These figures suggest that the stock may not be justified at its current price level.<BR><BR>In comparison to its peers, Bacil Pharma's valuation stands out unfavorably; for instance, MMTC has a PE ratio of 119.39, while PTC India, which is rated very attractive, has a significantly lower PE of 9.02. The PEG ratio for Bacil Pharma is notably low at 0.03, which could indicate potential growth, but the negative EV to EBIT and EV to EBITDA ratios of -24.51 raise serious concerns about profitability. Despite a strong one-year stock return of 70.54%, the year-to-date performance shows a decline of 27.35%, contrasting sharply with the Sensex's positive return of 5.63% in the same period, reinforcing the notion that Bacil Pharma may be overvalued.

What is the technical trend for Bacil Pharma?

As of May 26, 2025, Bacil Pharma shows a mildly bullish trend due to daily moving averages and monthly MACD signals, but mixed indicators from weekly MACD and Bollinger Bands suggest caution.

As of 26 May 2025, the technical trend for Bacil Pharma has changed from does not qualify to mildly bullish. The current stance is mildly bullish, driven by a bullish signal from the daily moving averages and a bullish monthly MACD. However, the weekly MACD and Bollinger Bands indicate a mildly bearish sentiment, suggesting some caution. The KST is bearish on the weekly but bullish on the monthly, adding to the mixed signals. Overall, while there are bullish indicators, the presence of bearish signals in the weekly timeframe indicates a lack of strong momentum.

How has been the historical performance of Bacil Pharma?

Bacil Pharma has not generated revenue from March 2019 to March 2025 but improved its financial position by reducing total expenditure and achieving a profit after tax of 0.40 crore in March 2025, recovering from previous losses. Additionally, total assets increased significantly from 1.27 crore in March 2024 to 25.55 crore in March 2025, indicating better asset management.

Answer:<BR>The historical performance of Bacil Pharma shows a consistent lack of revenue generation over the years, with net sales and other operating income remaining at zero from March 2019 to March 2025. Despite this, the company has seen a significant improvement in its profit metrics, achieving a profit after tax of 0.40 crore in March 2025, a notable recovery from losses in previous years, including a loss of 3.86 crore in March 2022. The total expenditure has decreased from 3.92 crore in March 2022 to 0.25 crore in March 2025, indicating improved cost management. The company's total assets have increased dramatically from 1.27 crore in March 2024 to 25.55 crore in March 2025, primarily driven by a rise in non-current investments. <BR><BR>Breakdown:<BR>Bacil Pharma's financial history reveals a persistent absence of sales and operating income from March 2019 through March 2025, with total operating income consistently recorded at zero. However, the company has made strides in reducing its total expenditure, which fell significantly from 3.92 crore in March 2022 to 0.25 crore in March 2025. This reduction in expenses has contributed to a turnaround in profitability, as evidenced by the profit after tax reaching 0.40 crore in March 2025, compared to substantial losses in prior years. The company's total assets have surged from 1.27 crore in March 2024 to 25.55 crore in March 2025, largely due to an increase in non-current investments, reflecting a strategic shift in asset allocation. Overall, while Bacil Pharma has not generated revenue, its improved financial management and asset growth indicate a potential for future stability.

When is the next results date for Bacil Pharma Ltd?

The next results date for Bacil Pharma Ltd is 13 February 2026.

The next results date for Bacil Pharma Ltd is scheduled for 13 February 2026.

Why is Bacil Pharma Ltd falling/rising?

As of 05-May, Bacil Pharma Ltd's stock price is at 54.99, down 1.24% and has declined 4.23% over the last three days. Despite a year-to-date increase of 54.29%, recent performance shows underperformance against its sector and moving averages, indicating a downward trend.

As of 05-May, Bacil Pharma Ltd's stock price is currently at 54.99, reflecting a decrease of 0.69, or 1.24%. The stock has been underperforming in the short term, having fallen consecutively for the last three days, resulting in a total decline of 4.23% during this period. Additionally, the stock's performance today has underperformed its sector by 0.77%. <BR><BR>In the context of broader market performance, Bacil Pharma Ltd has shown mixed results over different time frames. While it has a significant year-to-date increase of 54.29%, the stock has experienced a weekly decline of 1.79%, contrasting with a slight gain of 0.17% in the Sensex during the same period. <BR><BR>Despite the recent downturn, there is a notable increase in investor participation, with delivery volume rising by 35.17% compared to the 5-day average, indicating some level of interest from investors. However, the stock's moving averages suggest that it is currently lower than its 5-day and 20-day moving averages, which may contribute to the perception of a downward trend. <BR><BR>Overall, the combination of recent consecutive declines, underperformance against the sector, and the current price being lower than certain moving averages are key factors contributing to the stock's falling price.

Which are the latest news on Bacil Pharma?